Horama is developing gene therapies for rare retinal diseases. Its lead program is the most advanced gene therapy for the treatment PDE6β-related retinitis pigmentosa.

biopharmaceuticals
Private
Visit Website

http://www.horama.fr/

Additional Portfolio Companies
Adicet Bio
Adicet Bio
AgomAb Therapeutics
AgomAb Therapeutics
ArQule
ArQule
Cathworks
Cathworks
Camel-IDS
Camel-IDS
Dynacure
Dynacure
cCAM Biotherapeutics
cCAM Biotherapeutics
CheckCap
CheckCap
Eloxx Pharmaceuticals
Eloxx Pharmaceuticals
Enlivex Therapeutics
Enlivex Therapeutics
Entera Bio
Entera Bio
Eyevensys
Eyevensys
EyeYon
EyeYon
ForSight Vision6 (“V6”)
ForSight Vision6 (“V6”)
Horama
Horama
IMEL Biotherapeutics
IMEL Biotherapeutics
Kamari Pharma
Kamari Pharma
Keros Therapeutics
Keros Therapeutics
Kite Pharma
Kite Pharma
Levation Pharma
Levation Pharma
LogicBio Therapeutics
LogicBio Therapeutics
Lutris Pharma
Lutris Pharma
Metabomed
Metabomed
NovellusDX
NovellusDX
Novus Therapeutics
Novus Therapeutics
Ocon Medical
Ocon Medical
Prevail Therapeutics
Prevail Therapeutics
PACT Pharma
PACT Pharma
Pi Therapeutics
Pi Therapeutics
Protalix
Protalix
Raziel Therapeutics
Raziel Therapeutics
ReWalk
ReWalk
VBI Vaccines
VBI Vaccines
Step Pharma
Step Pharma
StimatixGI
StimatixGI
Sweetch
Sweetch
TargEDys
TargEDys
Vascular Graft Solutions
Vascular Graft Solutions
UroGen
UroGen
V-Wave
V-Wave
November 15, 2017